ARQT · NASDAQ
Arcutis Biotherapeutics (ARQT) Stock Price & Fundamentals
Arcutis Biotherapeutics (ARQT) closed at $440.75 on Oct 9, 2026, down 0.86% from the previous close of $444.57.
Share price, past year
1Y +10.04%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $440.75 |
| Sep 30, 2026 | $435.30 |
| Aug 31, 2026 | $432.19 |
| Jul 31, 2026 | $429.28 |
| Jun 30, 2026 | $430.79 |
| May 29, 2026 | $461.02 |
| Apr 30, 2026 | $466.62 |
| Mar 31, 2026 | $437.62 |
| Feb 27, 2026 | $443.62 |
| Jan 30, 2026 | $434.56 |
| Dec 31, 2025 | $435.02 |
| Nov 28, 2025 | $448.28 |
| Oct 31, 2025 | $436.42 |
Key statistics
- Market cap
- $55.35B
- P/E (TTM)
- 2,003.4
- EPS (TTM)
- $0.22
- Revenue (TTM)
- $463.98M
- Net income (TTM)
- $28.52M
- Shares outstanding
- 125.6M
- Dividend yield
- —
- 52-week range
- $400.55 – $472.10
Arcutis Biotherapeutics's market cap is $55.35B, based on a share price of $440.75 and 125.6M shares outstanding as of Jun 30, 2026.
Financials
Arcutis Biotherapeutics reported revenue of $376.07M for fiscal 2025, up 91.34% from fiscal 2024.
Arcutis Biotherapeutics reported a net loss of $16.14M in fiscal 2025.
Fiscal 2025 revenue was the highest in the 6 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $376.07M | +91.3% | −$16.14M | −4.3% | −$0.13 | −$6.31M |
| FY2024ended Dec 31, 2024 | $196.54M | +229.7% | −$140.04M | −71.3% | −$1.16 | −$112.30M |
| FY2023ended Dec 31, 2023 | $59.61M | +1,517.1% | −$262.14M | −439.8% | −$3.78 | −$247.49M |
| FY2022ended Dec 31, 2022 | $3.69M | — | −$311.46M | −8,449.8% | −$5.66 | −$258.05M |
| FY2021ended Dec 31, 2021 | $0.00 | — | −$206.36M | — | −$4.18 | −$175.62M |
| FY2020ended Dec 31, 2020 | $0.00 | — | −$135.68M | — | −$3.80 | −$113.35M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $129.86M | $15.01M | $0.11 |
| Q1 FY2026ended Mar 31, 2026 | $105.40M | −$11.30M | −$0.09 |
| Q4 FY2025ended Dec 31, 2025 | $129.50M | $17.40M | $0.14 |
| Q3 FY2025ended Sep 30, 2025 | $99.22M | $7.41M | $0.06 |
| Q2 FY2025ended Jun 30, 2025 | $81.50M | −$15.89M | −$0.13 |
| Q1 FY2025ended Mar 31, 2025 | $65.85M | −$25.06M | −$0.20 |
| Q4 FY2024ended Dec 31, 2024 | $71.36M | −$10.79M | −$0.09 |
| Q3 FY2024ended Sep 30, 2024 | $44.76M | −$41.54M | −$0.33 |
Company profile
- Name
- Arcutis Biotherapeutics, Inc.
- Ticker
- ARQT
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 3027 Townsgate Road, Suite 300, Westlake Village, CA 91361
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001787306
Recent SEC filings
- Aug 5, 2026
- Aug 5, 2026
- Jul 16, 2026
- Jun 9, 2026
- May 6, 2026
- May 6, 2026
- Feb 25, 2026
- Feb 25, 2026
Frequently asked questions
What is Arcutis Biotherapeutics's stock price?
Arcutis Biotherapeutics (ARQT) closed at $440.75 on Oct 9, 2026, down 0.86% from the previous close of $444.57.
What is Arcutis Biotherapeutics's market cap?
Arcutis Biotherapeutics's market cap is $55.35B, based on a share price of $440.75 and 125.6M shares outstanding as of Jun 30, 2026.
How much revenue does Arcutis Biotherapeutics make?
Arcutis Biotherapeutics reported revenue of $376.07M for fiscal 2025, up 91.34% from fiscal 2024.
What is ARQT's P/E ratio?
Arcutis Biotherapeutics's price-to-earnings ratio is 2,003.4, based on trailing twelve-month diluted EPS of $0.22.
Does Arcutis Biotherapeutics pay a dividend?
Arcutis Biotherapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Arcutis Biotherapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures